pyrroles has been researched along with Diabetic Nephropathies in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.11) | 18.2507 |
| 2000's | 8 (21.62) | 29.6817 |
| 2010's | 19 (51.35) | 24.3611 |
| 2020's | 7 (18.92) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S; Kashihara, N; Nangaku, M; Okuda, Y; Sawanobori, T; Shikata, K; Sugimoto, K; Wada, T | 1 |
| Akasaka, T; Hashimoto, M; Hosoya, T; Komoto, K; Murakami, K; Nakajima, H; Nakamura, A; Nunoue, T; Shiosakai, K; Sugimoto, K; Taguchi, T; Uchida, HA; Wada, J | 1 |
| Hao, D; Liu, X; Wang, X; Wang, Z; Yu, J | 1 |
| Cui, H; Ding, J; Jiang, L | 1 |
| Abe, M; Endo, M; Fukuda, N; Horikoshi, S; Okamura, M; Otsuki, M; Tsunemi, A | 1 |
| Rossing, P | 1 |
| Kanasaki, K; Koya, D; Kumagai, A; Liu, H; Takagaki, Y | 1 |
| Fu, J; Liu, L; Wang, LP; Xiu, ZM; Xu, J | 1 |
| Dong, P; Wang, YH; Wu, JJ; Zhang, M; Zhu, XN | 1 |
| Duggan, S | 1 |
| Du, Y; Gao, J; Hu, R; Lu, M; Wang, Y; Wei, W; Zhang, S; Zhou, Q; Zhu, H; Zuo, L | 1 |
| Deng, T; Li, H; Li, Y; Tian, L; Zhao, P; Zhou, S | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Drechsler, C; Genser, B; Hengstschläger, M; Kaltenecker, CC; Kopecky, C; Krane, V; März, W; Säemann, MD; Wanner, C; Weichhart, T | 1 |
| Campese, VM | 1 |
| Anzalone, DA; Cain, VA; Cressman, MD; de Zeeuw, D; Heerspink, HJ; Molitoris, BA; Monyak, JT; Parving, HH; Remuzzi, G; Sowers, JR; Vidt, DG | 1 |
| Haynes, R; Wanner, C | 1 |
| Du, M; Guo, F; Huang, F; Li, W; Ma, X; Qin, G; Wang, H; Wang, Q; Wu, L; Zhao, S | 1 |
| Angermann, C; Bauersachs, J; Frantz, S; Heinrich, F; Krane, V; Lilienthal, J; Meesmann, M; Olschewski, M; Störk, S; Wanner, C | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA | 1 |
| Kino, T; Matsuzawa, Y; Nishikawa, T; Omura, M; Saito, J; Suematsu, S | 1 |
| Charlton-Menys, V; Cruickshank, JK; Davies, RR; Dean, J; Durrington, PN; France, M; Gibson, JM; Gittins, M; Jinadev, P; Kalra, PA; Moorhouse, A; Prais, HR; Roberts, C; Rutter, MK; Wiles, PG | 1 |
| Advani, A; Cox, AJ; Gilbert, RE; Kelly, DJ; Wiggins, KJ; Zhang, Y | 1 |
| Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K | 1 |
| Chen, QJ; Lu, L; Peng, WH; Shen, WF; Wang, LJ; Wang, W | 1 |
| Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C | 1 |
| Huang, YJ; Li, Y; Wang, S | 1 |
| Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Yokote, K | 1 |
| Asmus, HG; Krämer, W; Krane, V; Kühn, KW; Kütemeyer, H; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Aso, Y; Inukai, T; Sekine, K; Takanashi, K; Takebayashi, K; Yoshida, N; Yoshihara, K | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Krane, V; Wanner, C | 1 |
| Chen, S; Kanwar, YS; Pyagay, PE; Sung, SH; Wang, A; Ziyadeh, FN | 1 |
| Horie, K; Iida, Y; Maeda, K; Miyata, T; Sugiyama, S; Tanaka, H; Tsuyuki, M | 1 |
| Horie, K; Kurokawa, K; Maeda, K; Miyata, S; Miyata, T; Monnier, VM; Sakai, H; Sugiyama, S; van Ypersole de Strihou, C; Witztum, JL | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
2 review(s) available for pyrroles and Diabetic Nephropathies
| Article | Year |
|---|---|
Advanced glycation end-products in diabetic nephropathy.
Topics: Animals; Arginine; Blood Glucose; Diabetic Nephropathies; Glycation End Products, Advanced; Glycosylation; Humans; Immunohistochemistry; Lysine; Norleucine; Proteins; Pyrroles | 1996 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
11 trial(s) available for pyrroles and Diabetic Nephropathies
| Article | Year |
|---|---|
Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.
Topics: Albumins; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Potassium; Pyrroles; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfones | 2022 |
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Germany; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins, HDL; Male; Middle Aged; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein B; Pyrroles; Renal Dialysis; Risk Factors; Serum Amyloid A Protein; Time Factors; Treatment Outcome | 2015 |
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
Topics: Adult; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Creatinine; Diabetes Complications; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Lipids; North America; Proteinuria; Pyrimidines; Pyrroles; Rosuvastatin Calcium; South America; Sulfonamides | 2015 |
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis.
Topics: Aged; Arrhythmias, Cardiac; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2009 |
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Aged; Albuminuria; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Topics: Albuminuria; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome; United Kingdom | 2011 |
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2004 |
Lessons learnt from the 4D trial.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Placebos; Pyrroles; Renal Dialysis | 2006 |
24 other study(ies) available for pyrroles and Diabetic Nephropathies
| Article | Year |
|---|---|
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
Topics: Albumins; Albuminuria; Blood Pressure; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Hypertension; Potassium; Prospective Studies; Pyrroles; Sulfones | 2022 |
Transcriptomic signatures responding to PKM2 activator TEPP-46 in the hyperglycemic human renal proximal epithelial tubular cells.
Topics: Biomarkers; Diabetic Nephropathies; ErbB Receptors; Glucose; Humans; MicroRNAs; Pyridazines; Pyrroles; Pyruvate Kinase; Pyruvic Acid; Transcriptome; Tumor Suppressor Protein p53 | 2022 |
Smad3 signalling affects high glucose-induced podocyte injury via regulation of the cytoskeletal protein transgelin.
Topics: Animals; Cell Line; Cytoskeletal Proteins; Diabetic Nephropathies; Glucose; Isoquinolines; Mice; Microfilament Proteins; Muscle Proteins; Phosphorylation; Podocytes; Proprotein Convertase 5; Pyridines; Pyrroles; Signal Transduction; Smad3 Protein; Sweetening Agents | 2020 |
Contribution of TGF-β1 and Effects of Gene Silencer Pyrrole-Imidazole Polyamides Targeting TGF-β1 in Diabetic Nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Silencing; Imidazoles; Male; Nylons; Pyrroles; Rats; Rats, Wistar; Transforming Growth Factor beta1 | 2020 |
Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Mineralocorticoid Receptor Antagonists; Pyrroles; Sulfones | 2020 |
The PKM2 activator TEPP-46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF-1α accumulation.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Fibrosis; Glycolysis; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney; Mice; Oxidative Phosphorylation; Pyridazines; Pyrroles; Pyruvate Kinase; Streptozocin | 2021 |
1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
Topics: Acetates; Aldehyde Reductase; Animals; Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Diabetic Nephropathies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Molecular Structure; Pyrroles; Rats; Streptozocin; Structure-Activity Relationship | 2017 |
[Correlation between expressions of VEGF and TRPC6 and their roles in podocyte injury in rats with diabetic nephropathy].
Topics: Animals; Chromones; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Indoles; Kidney; Membrane Proteins; Morpholines; Podocytes; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; TRPC Cation Channels; Vascular Endothelial Growth Factor A | 2018 |
Esaxerenone: First Global Approval.
Topics: Clinical Trials, Phase III as Topic; Diabetic Nephropathies; Drug Approval; Humans; Hypertension; Japan; Mineralocorticoid Receptor Antagonists; Molecular Structure; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Mineralocorticoid; Sulfones | 2019 |
Atorvastatin inhibits hyperglycemia-induced expression of osteopontin in the diabetic rat kidney via the p38 MAPK pathway.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Diabetic Nephropathies; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Kidney Glomerulus; Kidney Tubules; Lipids; Male; MAP Kinase Signaling System; Osteopontin; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Rats | 2014 |
Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Kidney; Lipoproteins, HDL; Lipoproteins, LDL; Male; Proteinuria; Pyrroles; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transforming Growth Factor beta1 | 2014 |
Statins and the kidney: friend or foe?
Topics: Diabetes Complications; Diabetic Nephropathies; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Pyrimidines; Pyrroles; Sulfonamides | 2015 |
Chronic kidney disease: Statins in chronic kidney disease: time to move on?
Topics: Diabetes Complications; Diabetic Nephropathies; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Pyrimidines; Pyrroles; Sulfonamides | 2015 |
Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo.
Topics: Animals; Azo Compounds; Desmin; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation; Glucose; Isoquinolines; Male; Membrane Proteins; Mice; Podocytes; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Pyrroles; Smad3 Protein; Transforming Growth Factor beta1 | 2016 |
Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).
Topics: Adolescent; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Atorvastatin; Biomarkers; Cardiomyopathies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Puberty; Pyrroles; Quinapril; Randomized Controlled Trials as Topic; Research Design; Risk; Tetrahydroisoquinolines | 2009 |
Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
Topics: Aldosterone; Angiotensin II; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP11B2; Diabetic Nephropathies; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Mesangial Cells; Pyrroles; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; ErbB Receptors; Female; Hypertrophy; Kidney; Mice; Podocytes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Transgenic; Renin; WT1 Proteins | 2011 |
Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
Topics: Animals; Atorvastatin; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; Streptozocin | 2011 |
[The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Gene Expression Regulation; Indoles; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Podocytes; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Vascular Endothelial Growth Factor A | 2011 |
Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Podocytes; Pyrroles | 2013 |
Dissociation between urinary pyrraline and pentosidine concentrations in diabetic patients with advanced nephropathy.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Arginine; beta 2-Microglobulin; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemoglobin; Humans; Lysine; Pyrroles; Reference Values; Regression Analysis | 2004 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Topics: Albuminuria; Animals; Diabetic Nephropathies; Indoles; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A | 2006 |
Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.
Topics: Adolescent; Adult; Aged; Animals; Antibodies; Arginine; Collagen; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycation End Products, Advanced; Humans; Immunoenzyme Techniques; Kidney Glomerulus; Lipid Peroxidation; Lysine; Male; Malondialdehyde; Mice; Middle Aged; Nephrotic Syndrome; Norleucine; Pyrroles; Rabbits | 1997 |